Breaking News

IPS Appoints Compliance Director for Latin Americas

April 10, 2013

DeSeabra brings 20 years of leadership experience

Alexandre José Jorge DeSeabra has been appointed director of compliance, Latin Americas, at IPS-Integrated Project Services, Inc. Mr. DeSeabra has more than 20 years of leadership and senior-level management experience in operations, quality assurance, quality control and compliance of global biomanufacturing facilities. His experience includes the start-up of three manufacturing companies, nine internationally compliant biologics manufacturing facilities and the successful manufacture of 14 licensed therapeutics.
Mr. DeSeabra has also established manufacturing, quality and compliance programs with companies including Tunnell Consulting and Kyamanox. He was recruited by TiGenix to establish manufacturing and quality operations for an autologous cell therapy-based product. Prior to that, he led development, documentation and commercialization efforts for OxThera.
“We are pleased to welcome Alex to IPS,” said Dave Goswami, PE, chief executive officer and chairman, IPS. “He brings a broad range of global biopharmaceutical experience, including cutting-edge technical expertise and extensive international compliance knowledge to help our multi-national clients maximize their growth potential. With our growing international business and our new focus on Latin Americas, Alex fulfills a key role in our growth. With the addition of Alex, IPS is well-positioned to achieve our clients’ strategic goals and business objectives in Brazil and other countries within Latin America.”

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important